PhII Alzheimer's fail­ure deals new blow to Roche, AC Im­mune — but the tau hy­poth­e­sis is far from dead

The lead­ing an­ti-tau an­ti­body has failed its first Phase II test­ing, cast­ing a shad­ow on a pop­u­lar tar­get (just trail­ing amy­loid be­ta) for Alzheimer’s dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER